Auransa to Receive Upfront Payment and be Eligible for Milestone Payments and Sales Royalties for Preclinical Program Identified by Company’s AI-Driven SMarTR™ Engine
Auransa Enters into Exclusive Licensing Agreement with China Oncology Focus Limited, an Affiliate of Lee’s Pharmaceutical Holdings, for Rights to AU018 in Greater China and Southeast Asia
Previous
Previous